Utilizing functional genomics screening to identify potentially novel drug targets in cancer cell spheroid cultures.
AffiliationThe Breast Cancer Now Toby Robins Research Centre, Division of Breast Cancer, The Institute of Cancer Research
MetadataShow full item record
AbstractThe identification of functional driver events in cancer is central to furthering our understanding of cancer biology and indispensable for the discovery of the next generation of novel drug targets. It is becoming apparent that more complex models of cancer are required to fully appreciate the contributing factors that drive tumorigenesis in vivo and increase the efficacy of novel therapies that make the transition from pre-clinical models to clinical trials. Here we present a methodology for generating uniform and reproducible tumor spheroids that can be subjected to siRNA functional screening. These spheroids display many characteristics that are found in solid tumors that are not present in traditional two-dimension culture. We show that several commonly used breast cancer cell lines are amenable to this protocol. Furthermore, we provide proof-of-principle data utilizing the breast cancer cell line BT474, confirming their dependency on amplification of the epidermal growth factor receptor HER2 and mutation of phosphatidylinositol-4,5-biphosphate 3-kinase (PIK3CA) when grown as tumor spheroids. Finally, we are able to further investigate and confirm the spatial impact of these dependencies using immunohistochemistry.
CitationUtilizing functional genomics screening to identify potentially novel drug targets in cancer cell spheroid cultures.. 2016 (118) J Vis Exp
JournalJournal of Visualized Experiments
- Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
- Authors: Maguire SL, Peck B, Wai PT, Campbell J, Barker H, Gulati A, Daley F, Vyse S, Huang P, Lord CJ, Farnie G, Brennan K, Natrajan R
- Issue date: 2016 Nov
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
- Authors: Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H
- Issue date: 2010 Feb
- Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA <sup>H1047R</sup> in HER2/ER-positive breast cancer.
- Authors: Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z
- Issue date: 2016 Dec
- Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
- Authors: Lopez S, Schwab CL, Cocco E, Bellone S, Bonazzoli E, English DP, Schwartz PE, Rutherford T, Angioli R, Santin AD
- Issue date: 2014 Nov
- Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.
- Authors: Halfter K, Hoffmann O, Ditsch N, Ahne M, Arnold F, Paepke S, Grab D, Bauerfeind I, Mayer B
- Issue date: 2016 May 3